Published in BMC Med Genomics on March 03, 2009
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res (2012) 2.10
The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway. Oncotarget (2014) 0.96
FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One (2012) 0.91
DNA methylation of NDRG2 in gastric cancer and its clinical significance. Dig Dis Sci (2012) 0.89
Expression of TIP30 tumor suppressor gene is down-regulated in human colorectal carcinoma. Dig Dis Sci (2009) 0.88
NDRG2 overexpression enhances glucose deprivation-mediated apoptosis in breast cancer cells via inhibition of the LKB1-AMPK pathway. Genes Cancer (2014) 0.85
Ndrg2 promoter hypermethylation triggered by helicobacter pylori infection correlates with poor patients survival in human gastric carcinoma. Oncotarget (2015) 0.84
Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression. BMC Cancer (2012) 0.83
Glioma Malignancy-Dependent NDRG2 Gene Methylation and Downregulation Correlates with Poor Patient Outcome. J Cancer (2014) 0.80
DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade. J Cancer Res Clin Oncol (2015) 0.78
N-myc downstream-regulated gene 2 (NDRG2) promoter methylation and expression in pituitary adenoma. Diagn Pathol (2017) 0.75
Identification and Validation of a Potential Marker of Tissue Quality Using Gene Expression Analysis of Human Colorectal Tissue. PLoS One (2015) 0.75
NDRG2 gene copy number is not altered in colorectal carcinoma. World J Clin Oncol (2017) 0.75
Expression of N-Myc Downstream-Regulated Gene 2 in Bladder Cancer and Its Potential Utility as a Urinary Diagnostic Biomarker. Med Sci Monit (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
The history of cancer epigenetics. Nat Rev Cancer (2004) 14.38
Cancer epigenetics comes of age. Nat Genet (1999) 12.63
Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res (1998) 8.95
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol (2004) 7.16
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet (2000) 6.57
Self-renewal and cancer of the gut: two sides of a coin. Science (2005) 5.44
Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR -- how well do they correlate? BMC Genomics (2005) 2.76
Epigenetic gene regulation: linking early developmental environment to adult disease. Reprod Toxicol (2006) 2.49
Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun (1983) 2.41
The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology (2000) 2.04
Relevance of DNA methylation in the management of cancer. Lancet Oncol (2003) 1.97
Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem (2002) 1.89
N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer (2003) 1.75
Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics (2001) 1.73
Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int J Colorectal Dis (2003) 1.69
Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res (2005) 1.66
Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res (2005) 1.63
Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol (1999) 1.49
Mechanisms of mineralocorticoid action. Hypertension (2005) 1.44
Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res (2005) 1.41
The necessity of a human epigenome project. Carcinogenesis (2006) 1.40
Identification of silencing of nine genes in human gastric cancers. Cancer Res (2002) 1.37
Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun (2007) 1.27
NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol (2004) 1.27
The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter. J Biol Chem (2006) 1.27
Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells. FEBS Lett (2003) 1.23
Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer (2007) 1.22
On the statistical assessment of classifiers using DNA microarray data. BMC Bioinformatics (2006) 1.18
Akt mediates insulin-stimulated phosphorylation of Ndrg2: evidence for cross-talk with protein kinase C theta. J Biol Chem (2004) 1.15
Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res (2002) 1.13
Quantitative DNA methylation analysis: the promise of high-throughput epigenomic diagnostic testing in human neoplastic disease. J Mol Diagn (2006) 0.99
The role of parental and grandparental epigenetic alterations in familial cancer risk. Cancer Res (2008) 0.90
Modulation of the Ca(2+)-activated Cl(-) channel by 14-3-3epsilon. Biochem Biophys Res Commun (2000) 0.83
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med (2005) 4.79
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet (2010) 4.65
High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. Am J Gastroenterol (2008) 3.31
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med (2012) 3.20
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology (2006) 3.14
Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature (2011) 2.59
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology (2007) 2.32
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology (2008) 2.28
Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure? Expert Opin Biol Ther (2012) 2.27
Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol (2006) 2.09
Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance. Liver Int (2013) 2.07
13C-aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C. J Hepatol (2011) 1.99
Randomized controlled trial of botulinum toxin versus laparoscopic heller myotomy for esophageal achalasia. Ann Surg (2004) 1.98
Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc (2002) 1.96
GOAL: automated Gene Ontology analysis of expression profiles. Nucleic Acids Res (2004) 1.79
Comparative study of gene set enrichment methods. BMC Bioinformatics (2009) 1.74
Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/macrothrombocytopenia) is the haematological presentation of phytosterolaemia. Br J Haematol (2005) 1.63
Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res (2010) 1.62
TRIM8 modulates p53 activity to dictate cell cycle arrest. Cell Cycle (2012) 1.56
Experts' opinions on the role of liver biopsy in HCV infection: a Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.). J Hepatol (2005) 1.55
NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet (2005) 1.53
Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol (2002) 1.51
Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol (2009) 1.50
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology (2009) 1.49
Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One (2012) 1.47
Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol (2008) 1.47
Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. Future Oncol (2013) 1.46
Activated innate immunity and the involvement of CX3CR1-fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney Int (2012) 1.46
Coarse nodular US pattern in hepatic cirrhosis: risk for hepatocellular carcinoma. Radiology (2003) 1.45
Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev (2009) 1.43
The intelligent, painless, "germ-free" colonoscopy: A Columbus' egg for increasing population adherence to colorectal cancer screening? Dig Liver Dis (2010) 1.41
Molecular and functional analysis of SUMF1 mutations in multiple sulfatase deficiency. Hum Mutat (2004) 1.36
Primary malignant melanoma of the esophagus: a clinicopathologic study of a case with comprehensive literature review. Adv Anat Pathol (2011) 1.33
Mutation spectrum of MLL2 in a cohort of Kabuki syndrome patients. Orphanet J Rare Dis (2011) 1.32
DPM2-CDG: a muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy. Ann Neurol (2012) 1.29
Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs (2010) 1.29
Aberrant DNA methylation in non-neoplastic gastric mucosa of H. Pylori infected patients and effect of eradication. Am J Gastroenterol (2007) 1.28
Mitochondrial DNA mutations in patients with postlingual, nonsyndromic hearing impairment. Eur J Hum Genet (2005) 1.27
Disruption of the ASTN2/TRIM32 locus at 9q33.1 is a risk factor in males for autism spectrum disorders, ADHD and other neurodevelopmental phenotypes. Hum Mol Genet (2013) 1.26
Side effects of genome structural changes. Curr Opin Genet Dev (2007) 1.22
Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol (2004) 1.20
Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets. Genome Res (2011) 1.20
Recurrent microdeletion at 17q12 as a cause of Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome: two case reports. Orphanet J Rare Dis (2009) 1.20
Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. Epigenetics (2011) 1.20
A modified fast-track program for pancreatic surgery: a prospective single-center experience. Langenbecks Arch Surg (2010) 1.19
The KCNQ1OT1 imprinting control region and non-coding RNA: new properties derived from the study of Beckwith-Wiedemann syndrome and Silver-Russell syndrome cases. Hum Mol Genet (2011) 1.17
New treatment approaches in renal cell carcinoma. Anticancer Drugs (2009) 1.17
Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics (2009) 1.16
Pathogenetic role of the deafness-related M34T mutation of Cx26. Hum Mol Genet (2006) 1.14
Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics (2011) 1.12
Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease--an IG-IBD study. Am J Gastroenterol (2005) 1.11
Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One (2013) 1.10
Fatal systemic venous air embolism during endoscopic retrograde cholangiopancreatography. Adv Anat Pathol (2009) 1.08
High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. J Hepatol (2002) 1.08
EUS-guided FNA of solid pancreatic masses with or without on-site cytological evaluation: more sample adequacy with less needle passes? Am J Gastroenterol (2012) 1.08
Changes in miR-143 and miR-21 expression and clinicopathological correlations in pancreatic cancers. Pancreas (2012) 1.06
Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study. Dig Liver Dis (2013) 1.06
Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol (2010) 1.06
Asp1424Asn MYH9 mutation results in an unstable protein responsible for the phenotypes in May-Hegglin anomaly/Fechtner syndrome. Blood (2003) 1.04
Large rearrangements detected by MLPA, point mutations, and survey of the frequency of mutations within the SLC3A1 and SLC7A9 genes in a cohort of 172 cystinuric Italian patients. Mol Genet Metab (2010) 1.04
Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond. World J Gastrointest Oncol (2010) 1.04
TBR1 is the candidate gene for intellectual disability in patients with a 2q24.2 interstitial deletion. Am J Med Genet A (2014) 1.04
Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. World J Gastroenterol (2006) 1.03
Italian consensus guidelines for chronic pancreatitis. Dig Liver Dis (2010) 1.02
Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family. Haematologica (2003) 1.01
High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. Int J Cancer (2010) 1.01
Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients. PLoS One (2011) 1.00
An atypical 7q11.23 deletion in a normal IQ Williams-Beuren syndrome patient. Eur J Hum Genet (2010) 1.00
Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol (2002) 0.99
Molecular analysis, pathogenic mechanisms, and readthrough therapy on a large cohort of Kabuki syndrome patients. Hum Mutat (2014) 0.99
The common -866G/A polymorphism in the promoter region of the UCP-2 gene is associated with reduced risk of type 2 diabetes in Caucasians from Italy. J Clin Endocrinol Metab (2004) 0.99
Mutation analysis of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the cationic trypsinogen (PRSS1) gene, and the serine protease inhibitor, Kazal type 1 (SPINK1) gene in patients with alcoholic chronic pancreatitis. Eur J Hum Genet (2003) 0.98